Matching grant to ADDIT-CE project
Project name: Alzheimer's Disease Diagnostics Innovation and Translation to Clinical Practice in Central Europe
Call: 09I01-03-V04 - Matching grants to resources obtained within the program Horizon 2020 and Horizon Europe
Investment: 1. Support for international cooperation and involvement in Horizon Europe projects and the EIT - European Institute of Innovation and Technology
Component: 9. More effective Management and strengthening of Research, Development and Innovation funding
Type of action: Recovery and Resilience Plan of the Slovak Republic 2021 - 2027 (RRP, Component 9)
Granting authority: Research Agency
Project starting date: 01/2024
Project end date: 06/2026
Project duration: 30 months
Estimated budget: 253 012,22 €
Abstract
Alzheimer's disease (AD) is a chronic, progressive disease of the nervous system based on the degenerative death of neurons with characteristic histopathological changes. AD is today the most common cause of dementia in middle and older age. The gradual extension of human life has become a very significant medical and socioeconomic problem.
The project focuses on the urgent need to improve the timely use of diagnostic tools for Alzheimer's disease (AD) and the potential of microRNA (miRNA) biomarkers.
Profiling the differences in miRNA expression between healthy individuals and early AD patients’ stages has great potential but is limited by technical obstacles. We intend to innovate to improve the preparation of miRNA libraries as well as investigate new methods of in situ detection of miRNA tissues. Together with the integration of laser microdissection will enable reliable cross-validation in the identification of miRNA biomarkers and their profiling in specific areas of interest.
The project follows on from the goals of the underlying Europe Horizon project with a scientific focus for early diagnosis of AD, increases its chance of success as well as wider impacts, and ultimately contributes to unlocking potential miRNA for diagnosis and eventual improvement of health care for patients with AD.
Project website: https://addit-ce.ceitec.cz/
Related News
Funded by the EU NextGenerationEU through the Recovery and Resilience Plan for Slovakia under the project No. 09I01-03-V04-00011.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
